OUR FOCUS

Neuroblastoma is a paediatric cancer that arises from the abnormal development of cells of the sympathetic nervous system. The average age at diagnosis is 17 months¹. Neuroblastomas account for close to 10% of all childhood cancers, yet cause 15% of childhood cancer deaths². This discrepancy reflects the variation in biological and clinical presentations of this disease. Whilst 90% of patients with low-risk disease are cured, less than 50% of patients with high-risk neuroblastoma go on to survive^2,3. There is a need for better treatment, particularly for high-risk children, where current treatments are highly intensive. This requires the development and commercialisation of improved therapeutics. Renaissance Pharma has recognised this need and, accordingly, Neuroblastoma represents our primary focus area.